{"id":509756,"date":"2021-07-06T09:03:30","date_gmt":"2021-07-06T13:03:30","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/ayala-pharmaceuticals-to-present-at-ladenburg-thalmann-healthcare-conference\/"},"modified":"2021-07-06T09:03:30","modified_gmt":"2021-07-06T13:03:30","slug":"ayala-pharmaceuticals-to-present-at-ladenburg-thalmann-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ayala-pharmaceuticals-to-present-at-ladenburg-thalmann-healthcare-conference\/","title":{"rendered":"Ayala Pharmaceuticals to Present at Ladenburg Thalmann Healthcare Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">REHOVOT, Israel &amp; WILMINGTON, Del., July  06, 2021  (GLOBE NEWSWIRE) &#8212; Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, today announced that Roni Mamluk, Ph.D., Chief Executive Officer of Ayala, will present at the Ladenburg Thalmann Healthcare Conference on Tuesday, July 13, 2021 at 9:00 am ET.<\/p>\n<p>A live webcast of each event may be accessed by visiting the Events &amp; Presentations section of Ayala\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=n10CCl6L3ap90DRtNln50e7HNVPPd7BzP1c4LmfcBB5i7h3C_9iIRo8Kt0JJcke751UxURe5M1IxsErosdjGaBF9T1mK2bxFFTMvDajZuWE=\" rel=\"nofollow noopener\" target=\"_blank\">ir.ayalapharma.com<\/a>. An archived replay of the webcast will be available on the website for approximately 90 days following the presentations.<\/p>\n<p>\n        <strong>About Ayala Pharmaceuticals<\/strong><br \/>\n        <br \/>Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. Ayala\u2019s approach is focused on predicating, identifying and addressing tumorigenic drivers of cancer through a combination of its bioinformatics platform and next-generation sequencing to deliver targeted therapies to underserved patient populations. The company has two product candidates under development, AL101 and AL102, targeting the aberrant activation of the Notch pathway with gamma secretase inhibitors to treat a variety of tumors including Adenoid Cystic Carcinoma, Triple Negative Breast Cancer (TNBC), T-cell Acute Lymphoblastic Leukemia (T-ALL), Desmoid Tumors and Multiple Myeloma (MM) (in collaboration with Novartis). AL101, has received Fast Track Designation and Orphan Drug Designation from the U.S. FDA and is currently in a Phase 2 clinical trial for patients with ACC (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=q_j1mY_A_jE1qhLNLpjg3rjhOfsgXB6mvyJ7JYB5w6y4RPm_9smYO7KN0vrW1K0i6UbZRjmHQ1k5Mm2JzebjrcH-BlhuRB7XIh3EqP5_IrND0Q5lBuDdaJ6YP3cn-GPaRcxPCTTrnatpPBYqLDh53BULi4TnmRlcEtRHy5FkXyL3p6gp7SnXWilJio0WCw5wFuWQPBPJCkf6TIuh1dV-6sSSUpWds6r8YwJX8JJEzb6ZyUP2drKb3mF8YkLiLHZW\" rel=\"nofollow noopener\" target=\"_blank\">ACCURACY<\/a>) bearing Notch activating mutations and in a Phase 2 clinical trial for patients with TNBC (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=3fUe_FTRYtWDuBhDWyndq-NLbLYhVbLJxx_16O96x4MBZBHwujaVarAv9q104B5ZZYymsNxLMj1XN6MdZwTBCsCvVhB_4hiSAYsHDjGFcy9uN-rW5fcicH0DMDY3WtNskxzw4QpnDOjQUisaiqbanyw7ffcc-t_BGujgyha1ycYVP4FKvoJ_C59aSlGp3tvDyhSOGU5Nhazf87V2UbCb8Z3-LkQtekc5rbP0gOZT5ccdA2z8vqC0wviN-DQLjjJ9MkjGvZu-Uxj34Wcl6fqiYxoDfbyNLGYA0Q95r9lTAknt53IIXlMLJNhiRIMzsSyz\" rel=\"nofollow noopener\" target=\"_blank\">TENACITY<\/a>) bearing Notch activating mutations and other gene rearrangements. AL102 is currently being advanced to a Phase 2\/3 clinical trials for patients with desmoid tumors (RINGSIDE) and is being evaluated in a Phase 1 clinical trial in combination with Novartis\u2019 BMCA targeting agent, WVT078, in Patients with relapsed\/refractory Multiple Myeloma. For more information, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gWJdSGUunLCqo5XeXZahcC24SEu0wSFDKpqdRtUdAgxubC6Scit2WSVyHHQykrTq_D_uBqkKwrsw7duS7f6RNtWnAAXvC7F9md94y9umn_M=\" rel=\"nofollow noopener\" target=\"_blank\">www.ayalapharma.com<\/a>.<\/p>\n<p>\n        <strong>Contacts:<\/strong>\n      <\/p>\n<p>\n        <strong>Investors:<\/strong><br \/>\n        <br \/>Julie Seidel<br \/>Stern Investor Relations, Inc. <br \/>+1-212-362-1200<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=TqI--rgkwzSiR9fW1-kI3_YkwqsxAfpuXvBOd3qa8xPDPdBr-13s_cZzrb7XOd8Z-z4MJUoOJrhJ8MooBTW_78s64BqeT7Ki8NQPfAPJs7M=\" rel=\"nofollow noopener\" target=\"_blank\">Julie.seidel@sternir.com<\/a><\/p>\n<p>\n        <strong>Ayala Pharmaceuticals:<\/strong><br \/>\n        <br \/>+1-857-444-0553<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=XtK-31R1wERjaIlkK9NFp7NWupLvtCR4buoqsYU1JnIsQF1_D6IWZVeOHZNupetCyw3CEkfOijVyQcJ7gMgic_LqQZk5-aJYftioP7j-ldk=\" rel=\"nofollow noopener\" target=\"_blank\">info@ayalapharma.com<\/a><\/p>\n<p>\u00a0<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NTU1NSM0MjgzNjQwIzIxOTUwMTI=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/e0fc84df-b22b-4202-983a-f2a63c21913c\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>REHOVOT, Israel &amp; WILMINGTON, Del., July 06, 2021 (GLOBE NEWSWIRE) &#8212; Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, today announced that Roni Mamluk, Ph.D., Chief Executive Officer of Ayala, will present at the Ladenburg Thalmann Healthcare Conference on Tuesday, July 13, 2021 at 9:00 am ET. A live webcast of each event may be accessed by visiting the Events &amp; Presentations section of Ayala\u2019s website at ir.ayalapharma.com. An archived replay of the webcast will be available on the website for approximately 90 days following the presentations. About Ayala Pharmaceuticals Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing and commercializing &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ayala-pharmaceuticals-to-present-at-ladenburg-thalmann-healthcare-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Ayala Pharmaceuticals to Present at Ladenburg Thalmann Healthcare Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-509756","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Ayala Pharmaceuticals to Present at Ladenburg Thalmann Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ayala-pharmaceuticals-to-present-at-ladenburg-thalmann-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ayala Pharmaceuticals to Present at Ladenburg Thalmann Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"REHOVOT, Israel &amp; WILMINGTON, Del., July 06, 2021 (GLOBE NEWSWIRE) &#8212; Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, today announced that Roni Mamluk, Ph.D., Chief Executive Officer of Ayala, will present at the Ladenburg Thalmann Healthcare Conference on Tuesday, July 13, 2021 at 9:00 am ET. A live webcast of each event may be accessed by visiting the Events &amp; Presentations section of Ayala\u2019s website at ir.ayalapharma.com. An archived replay of the webcast will be available on the website for approximately 90 days following the presentations. About Ayala Pharmaceuticals Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing and commercializing &hellip; Continue reading &quot;Ayala Pharmaceuticals to Present at Ladenburg Thalmann Healthcare Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ayala-pharmaceuticals-to-present-at-ladenburg-thalmann-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-06T13:03:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NTU1NSM0MjgzNjQwIzIxOTUwMTI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ayala-pharmaceuticals-to-present-at-ladenburg-thalmann-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ayala-pharmaceuticals-to-present-at-ladenburg-thalmann-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Ayala Pharmaceuticals to Present at Ladenburg Thalmann Healthcare Conference\",\"datePublished\":\"2021-07-06T13:03:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ayala-pharmaceuticals-to-present-at-ladenburg-thalmann-healthcare-conference\\\/\"},\"wordCount\":349,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ayala-pharmaceuticals-to-present-at-ladenburg-thalmann-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3NTU1NSM0MjgzNjQwIzIxOTUwMTI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ayala-pharmaceuticals-to-present-at-ladenburg-thalmann-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ayala-pharmaceuticals-to-present-at-ladenburg-thalmann-healthcare-conference\\\/\",\"name\":\"Ayala Pharmaceuticals to Present at Ladenburg Thalmann Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ayala-pharmaceuticals-to-present-at-ladenburg-thalmann-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ayala-pharmaceuticals-to-present-at-ladenburg-thalmann-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3NTU1NSM0MjgzNjQwIzIxOTUwMTI=\",\"datePublished\":\"2021-07-06T13:03:30+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ayala-pharmaceuticals-to-present-at-ladenburg-thalmann-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ayala-pharmaceuticals-to-present-at-ladenburg-thalmann-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ayala-pharmaceuticals-to-present-at-ladenburg-thalmann-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3NTU1NSM0MjgzNjQwIzIxOTUwMTI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3NTU1NSM0MjgzNjQwIzIxOTUwMTI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ayala-pharmaceuticals-to-present-at-ladenburg-thalmann-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ayala Pharmaceuticals to Present at Ladenburg Thalmann Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ayala Pharmaceuticals to Present at Ladenburg Thalmann Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ayala-pharmaceuticals-to-present-at-ladenburg-thalmann-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Ayala Pharmaceuticals to Present at Ladenburg Thalmann Healthcare Conference - Market Newsdesk","og_description":"REHOVOT, Israel &amp; WILMINGTON, Del., July 06, 2021 (GLOBE NEWSWIRE) &#8212; Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, today announced that Roni Mamluk, Ph.D., Chief Executive Officer of Ayala, will present at the Ladenburg Thalmann Healthcare Conference on Tuesday, July 13, 2021 at 9:00 am ET. A live webcast of each event may be accessed by visiting the Events &amp; Presentations section of Ayala\u2019s website at ir.ayalapharma.com. An archived replay of the webcast will be available on the website for approximately 90 days following the presentations. About Ayala Pharmaceuticals Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing and commercializing &hellip; Continue reading \"Ayala Pharmaceuticals to Present at Ladenburg Thalmann Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ayala-pharmaceuticals-to-present-at-ladenburg-thalmann-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-06T13:03:30+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NTU1NSM0MjgzNjQwIzIxOTUwMTI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ayala-pharmaceuticals-to-present-at-ladenburg-thalmann-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ayala-pharmaceuticals-to-present-at-ladenburg-thalmann-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Ayala Pharmaceuticals to Present at Ladenburg Thalmann Healthcare Conference","datePublished":"2021-07-06T13:03:30+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ayala-pharmaceuticals-to-present-at-ladenburg-thalmann-healthcare-conference\/"},"wordCount":349,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ayala-pharmaceuticals-to-present-at-ladenburg-thalmann-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NTU1NSM0MjgzNjQwIzIxOTUwMTI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ayala-pharmaceuticals-to-present-at-ladenburg-thalmann-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ayala-pharmaceuticals-to-present-at-ladenburg-thalmann-healthcare-conference\/","name":"Ayala Pharmaceuticals to Present at Ladenburg Thalmann Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ayala-pharmaceuticals-to-present-at-ladenburg-thalmann-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ayala-pharmaceuticals-to-present-at-ladenburg-thalmann-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NTU1NSM0MjgzNjQwIzIxOTUwMTI=","datePublished":"2021-07-06T13:03:30+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ayala-pharmaceuticals-to-present-at-ladenburg-thalmann-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ayala-pharmaceuticals-to-present-at-ladenburg-thalmann-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ayala-pharmaceuticals-to-present-at-ladenburg-thalmann-healthcare-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NTU1NSM0MjgzNjQwIzIxOTUwMTI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NTU1NSM0MjgzNjQwIzIxOTUwMTI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ayala-pharmaceuticals-to-present-at-ladenburg-thalmann-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Ayala Pharmaceuticals to Present at Ladenburg Thalmann Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/509756","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=509756"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/509756\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=509756"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=509756"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=509756"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}